WO2024236538 - AZETIDINE LINKED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS

National phase entry is expected:
Publication Number WO/2024/236538
Publication Date 21.11.2024
International Application No. PCT/IB2024/054799
International Filing Date 17.05.2024
Title **
[English] AZETIDINE LINKED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS
[French] COMPOSÉS HÉTÉROCYCLYLE BICYCLIQUES LIÉS À L'AZÉTIDINE EN TANT QUE MODULATEURS DE CCR4
Applicants **
AURIGENE ONCOLOGY LIMITED 39/40(P), KIADB Industrial Area, Electronics City Phase II, Bangalore, Karnataka- 560 100, IN
Inventors
ABBINENI, Chandrasekhar Plot#387, IKIGAI, Journalists’ colony phase 3, Gopanpally, Hyderabad, Telangana 500032, IN
SAMAJDAR, Susanta R801, HM Tambourine, JP Nagar 6th Phase, Bangalore, Karnataka 560078, IN
TALLURI, Krishna Chaitanya Flat No. 401, Srinadha Nilayam, opp. ALIND Employees colony park, Sudarshan Nagar, Lingampally, Hyderabad, Telangana 500019, IN
MUKHERJEE, Subhendu B208, SLV Sankalpa, Naganathapura, Central Jail Road, Bangalore, Karnataka 560100, IN
MIDUTURU, Chandrasekhar V 134 Vassal Ln, Cambridge, Cambridge, Massachusetts 02138, US
Priority Data
202341034417   17.05.2023   IN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
Sequence Listing *
International Search Report is established
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing2264
EPO Filing, Examination14828
Japan Filing560
South Korea Filing577
USA Filing, Examination15435
MasterCard Visa

Total: 33664

Abstract[English] The present disclosure provides azetidine linked bicyclic heterocyclyl compounds of formula (I-1), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the modulation of CCR4 activity. Compounds of the present disclosure are especially useful for treating cancer and inflammatory diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I-1) or a pharmaceutically acceptable salt or a stereoisomer thereof.[French] La présente divulgation concerne des composés hétérocyclyle bicycliques liés à l'azétidine de formule (I-1), qui sont thérapeutiquement utiles en tant que modulateurs de CCR4. Ces composés sont utiles dans le traitement et/ou la prévention de maladies et/ou de troubles sensibles à la modulation de l'activité de CCR4. Les composés selon la présente divulgation sont particulièrement utiles pour le traitement du cancer et de maladies et de troubles inflammatoires. La présente divulgation concerne également des procédés de préparation des composés et des formulations pharmaceutiques comprenant au moins l'un des composés de formule (I-1) ou un sel ou un stéréoisomère pharmaceutiquement acceptable de ceux-ci.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙